Advertisement
Australia markets closed
  • ALL ORDS

    7,974.80
    -27.70 (-0.35%)
     
  • ASX 200

    7,724.30
    -25.40 (-0.33%)
     
  • AUD/USD

    0.6618
    -0.0020 (-0.30%)
     
  • OIL

    78.49
    -0.13 (-0.17%)
     
  • GOLD

    2,348.40
    +30.40 (+1.31%)
     
  • Bitcoin AUD

    100,246.26
    -737.60 (-0.73%)
     
  • CMC Crypto 200

    1,401.41
    -16.47 (-1.16%)
     
  • AUD/EUR

    0.6178
    +0.0005 (+0.09%)
     
  • AUD/NZD

    1.0765
    +0.0012 (+0.12%)
     
  • NZX 50

    11,864.89
    -7.75 (-0.07%)
     
  • NASDAQ

    19,659.80
    +82.88 (+0.42%)
     
  • FTSE

    8,146.86
    -16.81 (-0.21%)
     
  • Dow Jones

    38,589.16
    -57.94 (-0.15%)
     
  • DAX

    18,002.02
    -263.66 (-1.44%)
     
  • Hang Seng

    17,941.78
    -170.85 (-0.94%)
     
  • NIKKEI 225

    38,814.56
    +94.09 (+0.24%)
     

Synlogic Reports First Quarter 2024 Financial Results

Synlogic, Inc.
Synlogic, Inc.

CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the first quarter 2024 and provided a corporate update.

In March 2024, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or other strategic transaction involving the Company. The Board has not set a timetable for the conclusion of this review, nor has it made any decisions related to any further actions or potential strategic options at this time. There can be no assurance, however, that this process will result in any such transaction.

First Quarter 2024 Financial Results

As of March 31, 2024 Synlogic had cash, cash equivalents, and short-term marketable securities of $32.3 million.

ADVERTISEMENT

Revenue was $0.01 million for the three months ended March 31, 2024, compared to $0.2 million for the corresponding period in 2023. Revenue for the three months ended March 31, 2024 was related to a material transfer agreement and revenue for the corresponding period in 2023 was associated with the prior research collaboration with Roche. Research and development expenses were $7.7 million for the three months ended March 31, 2024, compared to $12.5 million for the corresponding period in 2023. General and administrative expenses for the three months ended March 31, 2024 were $2.9 million compared to $4.0 million for the corresponding period in 2023. Restructuring and other charges were $28.2 million for the three months ended March 31, 2024, as a result of the Company’s decision in February 2024 to discontinue Synpheny-3, its pivotal study of labafenogene marselecobac (SYNB1934) in phenylketonuria (PKU) and evaluate strategic options for the Company.

For the three months ended March 31, 2024 Synlogic reported a consolidated net loss of $31.6 million, or $2.60 per share, compared to a consolidated net loss of $15.6 million, or $3.39 per share, for the corresponding period in 2023.

About Synlogic 

Synlogic is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases in need of new treatment options. Synlogic designs, develops and manufactures these drug candidates, which are produced by applying precision genetic engineering to well-characterized probiotics.

Forward Looking Statements

This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "look forward," "estimate," "expect," “focused on,” "intend," "on track, " "plan," "predict" and similar expressions and their variants, as they relate to Synlogic, may identify forward-looking statements. Actual results could differ materially from those contained in any forward-looking statements as a result of various factors, including: the Company may not execute on its planned exploration and evaluation of strategic alternatives; the availability of suitable third parties with which to conduct contemplated strategic transactions; the risk that the Company's reduction in force efforts may not generate their intended benefits to the extent or as quickly as anticipated; and the risk that the Company's reduction in force efforts may negatively impact the Company's business operations and reputation as well as those risks identified under the heading "Risk Factors" in Synlogic's filings with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Synlogic's current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic's view as of any date subsequent to the date hereof.

----
Contact: info@synlogictx.com




Synlogic, Inc.

 

 

 

 

Condensed Consolidated Statements of Operations

 

 

(unaudited)

 

 

 

 

 

 

 

 

 

(in thousands except share and per share data)

 

For the three months ended March 31

 

 

 

2024

 

 

 

2023

 

 

 

 

 

 

Revenue

 

$

8

 

 

$

174

 

 

 

 

 

 

Operating expenses

 

 

 

 

Research and development

 

 

7,680

 

 

 

12,450

 

General and administrative

 

 

2,884

 

 

 

3,967

 

Restructuring and other charges

 

 

28,289

 

 

 

-

 

Total operating expenses

 

 

38,853

 

 

 

16,417

 

Loss from operations

 

 

(38,845

)

 

 

(16,243

)

Other income

 

 

551

 

 

 

621

 

Fair value change in purchase warrant liability

 

 

6,730

 

 

 

-

 

Other income (expense), net

 

 

7,281

 

 

 

621

 

Net loss

 

$

(31,564

)

 

$

(15,622

)

 

 

 

 

 

Net loss per share - basic and diluted

 

$

(2.60

)

 

$

(3.39

)

Weighted-average common shares used in computing net loss per share - basic and diluted

 

 

12,131,461

 

 

 

4,604,682

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Synlogic, Inc.

 

 

 

 

Condensed Consolidated Balance Sheets

 

 

(unaudited)

 

 

 

 

 

 

 

 

 

(in thousands, except share data)

 

March 31,
2024

 

December 31,
2023

Assets

 

 

 

 

Cash, cash equivalents, & marketable securities

 

$

32,311

 

 

$

47,746

 

Property and equipment, net

 

 

-

 

 

 

5,603

 

Other assets

 

 

3,746

 

 

 

22,201

 

Total assets

 

$

36,057

 

 

$

75,550

 

 

 

 

 

 

Liabilities and stockholders' equity

 

 

 

 

Current liabilities

 

$

10,940

 

 

$

20,404

 

Long-term liabilities

 

 

11,792

 

 

 

12,491

 

Total liabilities

 

 

22,732

 

 

 

32,895

 

Total stockholders' equity

 

 

13,325

 

 

 

42,655

 

Total liabilities and stockholders' equity

 

$

36,057

 

 

$

75,550

 

 

 

 

 

 

Common stock and common stock equivalents

 

 

Common stock

 

 

11,627,212

 

 

 

9,186,157

 

Common stock warrants (pre-funded)

 

 

722,183

 

 

 

2,973,183

 

Total common stock

 

 

12,349,395

 

 

 

12,159,340